Early Assessment of COVID-19 epidemiology and Vaccine/anti-viral Effectiveness (EAVE II)

苏格兰是开展这项研究的理想地点，因为每个人都有一个独特的参考号码。这样就可以很容易地将不同的健康数据集连接在一起，并根据250个普通诊所和120万个人（占人口的22%）的数据构建一个电子队列。如此庞大的队列，提供了广泛的区域覆盖，并允许对5岁以下儿童或65岁以上成年人等亚群体进行调查。这些数据已经被收集用于日常护理——关于全科医生咨询、处方、非工作时间咨询、事故和急诊使用以及住院情况的信息。它还包括用于诊断冠状病毒，特别是COVID-19患者的实验室测试。个人将接受常规血液检查，未使用的血液样本将被储存起来，并最终检测是否存在COVID-19抗体，以计算出疫情期间暴露的人口比例。我们还将从患者样本中对病毒基因组进行测序。这些数据的分析是在一个安全的避风港使用匿名数据进行的，因此无法识别个人身份。将对该队列进行随访，以监测COVID-19流行的进展，并评估哪些干预措施对治疗和预防该病毒有效。

Scotland is an ideal place to carry out this research as there is a unique reference number for every individual. This makes it easy to link together different health datasets and construct an electronic cohort based upon data from 250 general practices and 1.2m individuals (22% of the population). Such a large cohort, gives wide regional coverage and permits investigation of subgroups such as children aged under 5 or adults over 65.These data are already being collected for routine care - information on GP consultations, prescriptions, out of hours’ consultations, use of accident and emergency and hospital admissions. It also includes laboratory tests to diagnose a person with coronavirus and specifically COVID-19. Individuals will be having routine blood tests and a sample of unused blood will be stored and eventually tested for the presence of COVID-19 antibodies to work out the proportion of the population exposed during the epidemic. We will also sequence virus genomes from a sample of patients. The analysis of these data is carried out in a safe haven using anonymised data so that individuals cannot be identified.This cohort will be followed up to monitor the progress of the COVID-19 epidemic and to evaluate which interventions are effective for treating and preventing the virus.